SURVIVAL AFTER TRANSURETHRAL AND TRANSVESICAL SURGERY IN LOCALIZED CANCER OF THE PROSTATE, NORWAY 1957-1981

被引:0
|
作者
HARVEI, S [1 ]
SANDER, S [1 ]
TRETLI, S [1 ]
LANGMARK, F [1 ]
机构
[1] AKER HOSP, DEPT UROL, OSLO 5, NORWAY
关键词
PROSTATE; NEOPLASMS; SURGERY; TRANSURETHRAL; TRANSVESICAL; SURVIVAL; REGISTRY DATA;
D O I
10.1002/1097-0142(19930615)71:12<3966::AID-CNCR2820711227>3.0.CO;2-H
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. During the period 1957-1981, there has been a gradual change in the choice of surgical methods for patients with prostate cancer in Norway, from transvesical surgery to transurethral resections (TUR-P). Radical prostatectomy was practically nonexistent in the early years of this time period. Sixty-five percent (17,696 patients) of all patients with prostate cancer reported to the Cancer Registry had no metastases at the time of diagnosis. Of these, 5414 patients underwent TUR-P, whereas 6160 patients underwent transvesical operations as primary surgery. Interest was raised in analyzing survival after primary surgery. Methods and Results. Five-year relative survival rates were calculated for the groups of patients undergoing each type of surgery; the rates increased steadily for both groups during the later years of the 1957-1981 period. However, survival consistently was better for patients who had transvesical surgery. The difference in 5-year relative survival rates was 10-15%. The same pattern was seen long-term survival (more than 10 years). In addition, survival rates for patients with similar grade of tumor differentiation were better for patients undergoing transvesical surgery. A multivariate analysis of survival that related age, surgical methods, grades of tumor differentiation, and diagnostic periods showed that survival was influenced most by differentiation, followed by surgery. Age was not an important factor in this analysis. Conclusions. The results underline the importance of additional research regarding the precise classification of prostatic cancer at the time of diagnosis so that clinicians can better choose the proper method of surgery.
引用
收藏
页码:3966 / 3971
页数:6
相关论文
共 50 条
  • [41] Neutrophil Count is Associated With Survival in Localized Prostate Cancer
    Bahig, H.
    Delouya, G.
    Soulieres, D.
    Nadiri, A.
    Jacques, A. Gagnon
    Paule, B. C.
    Taussky, D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E252 - E252
  • [42] PREDICT: Model for prediction of survival in localized prostate cancer
    Kerkmeijer, L. G. W.
    Monninkhof, E. M.
    Van Oort, I. M.
    Van der Poel, H. G.
    De Meerleer, G.
    Van Vulpen, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S54 - S54
  • [43] Survival analysis of localized prostate cancer with deep learning
    Xin Dai
    Ji Hwan Park
    Shinjae Yoo
    Nicholas D’Imperio
    Benjamin H. McMahon
    Christopher T. Rentsch
    Janet P. Tate
    Amy C. Justice
    [J]. Scientific Reports, 12
  • [44] PREDICT: model for prediction of survival in localized prostate cancer
    Linda G. W. Kerkmeijer
    Evelyn M. Monninkhof
    Inge M. van Oort
    Henk G. van der Poel
    Gert de Meerleer
    Marco van Vulpen
    [J]. World Journal of Urology, 2016, 34 : 789 - 795
  • [45] PREDICT: model for prediction of survival in localized prostate cancer
    Kerkmeijer, Linda G. W.
    Monninkhof, Evelyn M.
    van Oort, Inge M.
    van der Poel, Henk G.
    de Meerleer, Gert
    van Vulpen, Marco
    [J]. WORLD JOURNAL OF UROLOGY, 2016, 34 (06) : 789 - 795
  • [46] Neutrophil count is associated with survival in localized prostate cancer
    Bahig, Houda
    Taussky, Daniel
    Delouya, Guila
    Nadiri, Amal
    Gagnon-Jacques, Ariane
    Bodson-Clermont, Paule
    Soulieres, Denis
    [J]. BMC CANCER, 2015, 15
  • [47] Neutrophil count is associated with survival in localized prostate cancer
    Houda Bahig
    Daniel Taussky
    Guila Delouya
    Amal Nadiri
    Ariane Gagnon-Jacques
    Paule Bodson-Clermont
    Denis Soulieres
    [J]. BMC Cancer, 15
  • [48] Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer
    See W.A.
    [J]. Current Treatment Options in Oncology, 2003, 4 (5) : 351 - 362
  • [49] Prognostic factors of detectable PSA after radical surgery for clinically localized prostate cancer
    Naselli, A.
    Andreatla, R.
    Fontana, V
    Puppo, P.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 280 - 280
  • [50] Cancer incidence after localized therapy for prostate cancer
    Moon, Kihyuck
    Stukenborg, George J.
    Keim, Jessica
    Theodorescu, Dan
    [J]. CANCER, 2006, 107 (05) : 991 - 998